Cardiol Rev . A Review of Remdesivir for COVID-19: Data to Date

[tetano]

Cardiol Rev


. 2020 Aug 10.
doi: 10.1097/CRD.0000000000000337. Online ahead of print.
A Review of Remdesivir for COVID-19: Data to Date


Monica Mehta ¹ , Grace Shyh



Affiliations

• PMID: 32773440
• DOI: 10.1097/CRD.0000000000000337

Abstract

Severe acute respiratory coroniavirus-2 (SARS-CoV-2) is the virus responsible for the greatest public health challenge of our lifetime, the Coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated post-infection sequelae and grave consequences, suffice to say that the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues around accessibility.